Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Audit Information

v3.26.1
Audit Information
 12 Months Ended
Dec. 31, 2025
Auditor [Line Items]  
Auditor Name KOST FORER GABBAY& KASIERER
Auditor Firm ID 1281
Auditor Location Tel-Aviv, Israel
Auditor Opinion [Text Block]

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Can-Fite BioPharma Ltd. and its subsidiary (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operating loss, changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.